Best practice molecular diagnostic reference standards require international collaboration.
Information on lifestyle management, physical therapy and bone health were provided.
Respiratory and extramuscular complications and options for palliative therapy were discussed.
Potential investigative disease-modifying agents for FSHD were identified.
The role and requirements for FSHD registries were explored.